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Abstract: Clear cell renal cell carcinoma (ccRCC) is characterized by stabilization of hypoxia-inducible factor (HIF1), 
and mutations in von Hippel-Lindau (VHL) gene. Additionally, in about 40% of ccRCC cases the mutation in PBRM1 
(POLYBROMO1) gene coding for a non-core subunit of SWI/SNF chromatin remodeling complex was found suggest-
ing potential impairment of this complex function in ccRCC. In this study we assessed the extent to which the core 
SWI/SNF complex subunit - INI1 (hSNF5/SMARCB1) is affected in ccRCC and whether it has any consequences 
on the development of this type of cancer. The evaluation of INI1 protein level in samples from 50 patients with 
diagnosed ccRCC, including three displaying rhabdoid features, showed the INI1 positive staining in rhabdoid cells 
while the conventional ccRCC cells exhibited reduced INI1 level. This indicated the rhabdoid component of ccRCC as 
distinct from other known rhabdoid tumors. The reduced INI1 protein level observed in all conventional ccRCC cases 
used in this study correlated with decreased SMARCB1 gene expression at the transcript level. Consistently, the 
overexpression of INI1 protein in A498 ccRCC cell line resulted in the elevation of endogenous SMARCB1 transcript 
level indicating that the INI1-dependent regulatory feedback loop controlling expression of this gene is affected in 
ccRCC Moreover, the set of INI1 target genes including i.e. CXCL12/CXCR7/CXCR4 chemokine axis was identified 
to be affected in ccRCC. In summary, we demonstrated that the inactivation of INI1 may be of high importance for 
ccRCC development and aggressiveness.
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Introduction
Renal cell carcinoma (RCC) is the most com-
mon type of malignant adult kidney tumor [1]. 
Approximately 75% of RCC cases represents 
the clear cell renal cell carcinoma subtype 
(ccRCC) [2]. ccRCC is characterized by glycogen 
and fatty acid accummulation in tumour cells 
[3]. These metabolic changes are associated 
with stabilization of hypoxia-inducible factor 
(HIF1) and mutations in von Hippel-Lindau 
(VHL) gene which occur in about 90% of ccRCC 
tumors [4, 5]. Further study showed that about 
40% of ccRCCs demonstrate mutations of 
PBRM1 (POLYBROMO1) a gene coding for the 
non-core subunit of SWI/SNF chromatin remod-
eling complex (CRC) [6]. Therefore, the PBRM1 
is the second most frequently mutated gene in 
ccRCC after VHL [7].
About 30% of primary ccRCC patients develop 
metastases, and further 20 to 40% of patients 
show recurrence after cancer resection [8]. This 
type of cancer is additionally highly resistant to 
classical chemotherapy and shows modest 
response to targeted therapy, therefore under-
standing molecular mechanism of ccRCC 
tumorigenesis, progression and metastases 
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formation is vital and may lead to the develop-
ment of new forms of therapy. 
The occurrence of mutation in PBRM1 gene in 
ccRCC suggests that in this type of cancer the 
function of the whole SWI/SNF chromatin 
remodeling complex may be affected, which is 
commonly observed for other cancer types. It 
has been reported that genes coding for SWI/
SNF subunits are frequently mutated in various 
types of cancer including lung cancer, ovarian 
cancer, synovial sarcoma, breast cancer, mela-
noma, pancreatic cancer, Burkitt’s lymphoma, 
etc. [9]. The SWI/SNF is an evolutionarily con-
served multisubunit protein complex, involved 
in transcriptional control of gene expression in 
the ATP-dependent manner. In most tissue 
types this complex is composed of the function-
al core: SWI2/SNF2 type ATPase - BRM or 
BRG1, one SNF5-type subunit - the SNF5/
BAF47/INI1 protein (called INI1 in this work) 
and two SWI3 type subunits BAF155 and 
BAF170 along with several non-core accessory 
subunits [10].
Two classes of SWI/SNF CRC exist in human 
cells: BAF and PBAF. Both BAF and PBAF are 
multisubunit molecular complexes which carry 
a set of common subunits and show differenc-
es in composition of their accessory subunits. 
The most important subunits distinguishing 
BAF and PBAF SWI/SNF CRCs are: BAF250a 
and b encoded by ARID1A and ARID1B genes 
(for BAF complex), and BAF180 encoded by 
PBRM1 gene frequently mutated in ccRCC (for 
PBAF complex) [6, 9]. Lack of BRM - an ATPase 
subunit of SWI/SNF complex was found in poor-
ly differentiated ccRCC [11], while the ARID1A 
gene coding for BAF250a SWI/SNF subunit has 
recently been described as new prognostic 
marker for ccRCC [12]. Biallelic loss of SM- 
ARCB1 gene coding for INI1 was observed in 
pediatric malignant rhabdoid tumors (MRT) 
[13, 14]. Additionally, loss of INI1 was identified 
in epithelioid sarcoma, schwannomatosis, mul-
tiple meningiomas and renal medullary carci-
noma [9, 15]. The available data on INI1 protein 
abundance in ccRCC is limited and contradic-
tory. A case of rhabdoid RCC with minute focus 
ccRCC component featured by the loss of INI1 
protein has been recently reported [16]. In 
another report Agaimy et al. [17] found loss of 
SWI/SNF core subunits other than INI1 in RCC 
with rhabdoid features, while INI1 protein level 
was mostly not altered. 
In this study we investigated the expression of 
INI1 protein in 50 ccRCC samples. Three of 
them showed a rhabdoid component repre-
senting 10-20% of tumor tissue. Our analysis 
indicated that the INI1 protein level was not 
decreased in the rhabdoid cells of ccRCC with 
rhabdoid component. Simultaneously we found 
decreased level of INI1 in non-rhabdoid ccRCC 
cells when compared to normal kidney tube 
epithelial cells. Further investigation of the 
remaining 47 cases with conventional ccRCC 
indicated substantial decrease of INI1 protein 
in cancer cells. Moreover, the reanalysis of 
transcriptomic data available for ccRCC indi-
cated significant correlation between distur-
bances in SMARCB1 gene expression and poor 
prognosis. Comparative analysis of transcrip-
tomic datasets of ccRCC samples available in 
public sources and datasets from genome-wide 
INI1 distribution study resulted in the identifica-
tion of INI1-dependent genes with misregulated 
expression in ccRCC. Among them the subse-
quent Gene Ontology analysis identified genes 
belonging to carcinogenesis related GO terms. 
The overexpression of INI1 in A498 renal cell 
line resulted in the substantially decreased 
expression of CXCR4 and CXCR7 genes belong-
ing to CXCL12/CXCR7/CXCR4 axis. Moreover, 
the A498 line overexpressing INI1 protein 
exhibited elevated expression of the endoge-
nous SMARCB1 transcript suggesting the 
impairment of INI1-dependent regulatory feed-
back loop controlling SMARCB1 expression in 
ccRCC. Collectively, our findings suggest impor-
tant role of INI1 in ccRCC development, pro-
gression and metastasis. 
Materials and methods
Patients
We retrospectively analyzed formalin-fixed, 
paraffin-embedded as well as snap frozen sam-
ples from 50 patients with ccRCC diagnosed 
between January 2013 and December 2016 in 
two Polish hospitals: The Maria Sklodowska-
Curie Memorial Cancer Center in Warsaw and 
Hospital of Ministry of Interior in Bialystok. All 
samples were re-reviewed by a pathologist for 
Fuhrman grade, tumor stage and the presence 
of additional histological components. 
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Tissue microarray and immunohistochemistry
Tissue array was prepared using Quick-Ray 
Tissue Microarrayer according to producer 
instruction. Hematoxylin and eosin stained 
slides from paraffin embedded ccRCC samples 
were used to identify ccRCC and normal kidney 
tissue, later submitted for tissue microarray.
Immunohistochemical analysis was performed 
on 4-μm tissue sections of paraffin embedded 
tumor and reference tissue using the EnVision 
FLEX+, Mouse, High pH Detection System 
(Dako, Glostrup, Denmark). Sections were 
deparaffinized with xylene and rehydrated in 
ethanol solutions. Heat-induced epitope retriev-
al was performed in Target Retrieval Solution 
(Dako) for 20 minutes at 96°C. After cooling, 
the slides were treated for 5 minutes with an 
endogenous peroxidase blocker (Dako), fol-
lowed by incubation with monoclonal antibody 
against INI1 [monoclonal antibody SNF5 
(D9C2), Cell Signalling Technology] for 30 min-
utes at room temperature, and then labeled 
with the EnVision FLEX+, Mouse, High pH 
Detection System (Dako). The color reaction 
product was developed with 3,3’-diaminobenzi-
dine tetrahydrochloride (Dako) as a substrate. 
Nuclear contrast was achieved with hematoxy-
lin counterstaining by 1 minute.
Protein isolation and western blot
Total protein extract was isolated from 30 mg 
of snap frozen ccRCC and normal kidney tissue 
samples using 8 M urea buffer. On each lane 
30 µg of total protein extracts were loaded. 
Proteins were separated on 12% SDS-PAGE 
containing 0.5% TCE and visualized on UV to 
assess proper loading in each lane. Subse- 
quently, separated proteins were transferred 
on PVDF membrane (Millipore). TBS with 5% 
BSA was used to block non-specific antibody 
binding. After blocking, membranes were incu-
bated overnight at 4°C with anti-FLAG antibody 
(Cell Signaling Technology) or anti-INI1 antibody 
(Cell Signaling Technology) in 1:1000 dilution 
in TBS containing 5% BSA. Samples were 
then washed twice and incubated 60 minutes 
with anti-rabbit secondary antibody (Bio-Rad) 
diluted 1:10000. The signal was detected 
by WesternBright Quantum chemiluminescent 
detection kit (Advansta) using X-ray films 
(Amersham) or chemiluminescent documenta-
tion system (depending on the necessity).
RNA extraction and qRT-PCR
Total RNA was isolated from 30 mg of fresh fro-
zen material or cell culture using RNA Isolation 
Kit (Qiagen) according to protocol. The reverse 
transcriptase reaction was performed using 
Transcriptor First Strand cDNA Synthesis Kit 
(Roche). Expression of SMARCB1 gene was 
measured by SybrGreen (BioRad) with UBIQ- 
UITIN as reference gene using following prim-
ers: 5’GACCAGGACAGGAACACGAG3’, 5’CAAA- 
TGGAATGTGTGCCGG3’ for SMARCB1, and 
5’ATTTGGGTCGCGGTTCTTG3’, 5’TGCCTTGACA- 
TTCTCGATGGT3’ for UBI. Primers for CXCR4 
was obtained from qPrimerDepot database 
[18] 5’CTTGTCCGTCATGCTTCTCA3’, 5’CTTGT- 
CCGTCATGCTTCTCA and for CXCR7 from 
Berahovich [19] 5’AGCACAGCCAGGAAGGCG- 
AG3’, 5’TCATAGCCTGTGGGTCTTCCG3’.
Cell culture and transfection
A498 human renal cancer cell line (obtained 
from ATCC) was grown in RPMI 1640 (Biowest) 
with 10% Fetal Bovine Serum (FBS) (Biowest) 
and 1% penicillin/streptomycin (Gibco) in 
humidifier incubator (37°C and 5% CO2) accord-
ing to manufacturer instruction.
Cloning and overexpression of INI1 protein in 
A498 cell line
cDNA coding for INI1 protein with FLAG-tag 
obtained from Addgene collection (Plasmid 
#1953) in vector pFastBac1 INI1 provided by 
Robert Kingston [20] was moved on EcoRI 
restriction site into pcDNA3.1 mammalian 
expression vector. A498 cell transfection was 
performed using TurboFect reagent (Thermo 
Fisher) according to protocol. Cells were col-
lected 48 h post transfection. As mock control 
empty pcDNA3.1 was used. 
Microarray analysis
The microarray datasets obtained from Gene 
Omnibus Database (GEO; GSE36895) from 29 
ccRCC samples and 24 normal kidney cortex 
samples [21] were reanalyzed using GeneSpring 
GX software (Agilent) according to guided work-
flow with 1.45 fold change. All 24 normal kidney 
cortex samples were normalized and treated as 
normal, and all 29 ccRCC samples were nor-
malized and treated as cancer sample.
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Statistics
Statistical analysis was performed using 
MedCalc software and GraphPad Prism 5.0 by 
Shapiro-Wilk normality test, paired t-test, 
Mann-Whitney rank test for independent sam-
ples and multiple regression. P value <0.05 
was considerated as statistically significant. 
Cox Proportional Hazard regression was used 
for estimation the relationship between the 
gene expression and survival rate using Surv- 
Express platform [22] and data obtained from 
GEO database GSE3538 containing additional 
clinical information: grade, performance sta-
tus, gender, age and stage of the disease [23]. 
With three ccRCC tumors with rhabdoid compo-
nent in our study group we decided to assess 
INI1 protein level. Interestingly, we found spe-
cific INI1 positive staining in rhabdoid cells of 
all 3 cases (Figure 1A), which confirmed the 
suggestion of Kryvenko and collages [24] that 
rhabdoid RCC is different from malignant rhab-
doid tumors. Observed INI1 staining was even 
stronger in rhabdoid cells compared to normal 
kidney proximal tube epithelial cells. Strikingly, 
we found significant decrease of INI1 protein 
abundance in conventional ccRCC cells. This 
observation was an indication that the rhab-
doid component of ccRCC differs from conven-
tional ccRCC cell also at the INI1 protein level. 
Table 1. Clinical and histopathological characteristic of 
the patients. N/A, data not available
Characteristics n (%)
Gender
    Female 19 (38%)
    Male 31 (62%)
Age
    <60 16 (32%)
    ≥60 34 (68%)
Fuhrman gradea
    G1 6 (12.2%)
    G2 22 (44.9%)
    G3 18 (36.8%)
    G4 3 (6.1%)
pT categoryb
    pT1 26 (53%)
    pT2 4 (8.2%)
    pT3 9 (18.4%)
    pT4 1
    NA 9 (18.4%)
Tumor max diameter (cm)
    <7 32 (64%)
    ≥7 18 (36%)
Type
    ccRCC 47 (94%)
    ccRCC with rhabdoid features 3 (6%)
Metastasis
    N/A 20 (40%)
    No metastasis 20 (40%)
    Metastasis 10 (20%)
    Female 2 (20% of total metastasis)
    Male 8 (80% of total metastasis)
abased on Fuhrman grade classification; baccording to pTNM clas-
sification.
Two risk groups were generated using the 
prognostic index median. Log-rank test 
was used to evaluate the equality of sur-
vival curves [22]. 
Results
Clinical features of patients
The clinicopathological features of pa- 
tients enrolled in this study are detailed in 
Table 1. A total of 50 cases were analyzed. 
Patients were 19 females and 31 males 
aged 34 to 83 years (mean, 69). There 
were statistical differences in the gender 
(male 62% and woman 38%) but no differ-
ences in distribution of the age in these 
groups. More than 80% of all patients had 
G2 and G3 Fuhrman grade tumors while 
53% of studied cases were stage pT1 
according to pTNM/AJCC. Three samples 
of ccRCC showed a rhabdoid component 
representing 10-20% of tumor tissue. Ten 
patients had metastatic disease at the 
time of diagnosis, 2 (20%) of them were 
female and 8 (80%) were male. 
INI1 positive staining in rhabdoid cells in 
ccRCC with rhabdoid component
Typical rhabdoid tumors are INI1 negative 
due to mutation in SMARCB1 - INI1 encod-
ing gene [13, 14]. The case report pub-
lished for rhabdoid RCC with minute ccRCC 
component [16] showed loss of INI1 pro-
tein in the rhabdoid cells while another 
report [17] showed that the loss of INI1 
protein is rarely observed in RCC with 
rhabdoid component including ccRCC. 
INI1 in ccRCC
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However, this finding did not provide informa-
tion if the decrease of INI1 protein level in con-
ventional component of ccRCC is a general fea-
ture for all ccRCC cases or just restricted to 
cases with rhabdoid features.
INI1 is downregulated in ccRCC cells 
Given the observed decreased INI1 protein 
abundance in the conventional component of 
ccRCC with rhabdoid features, we decided to 
examine further 47 ccRCC cases for INI1 ex- 
pression using immunostaining on paraffin 
embedded samples with INI1 specific antibody. 
We found significant decrease of INI1 staining 
in ccRCC cancer cells in comparison to normal 
kidney tube epithelial cells (Figure 1B and 1C) 
which suggests the INI1 protein decrease may 
be a general feature of ccRCC. To confirm the 
IHC results the western blot analysis was per-
Figure 1. Downregulation of INI1 in ccRCC cells but not in rhabdoid cells in ccRCC with rhabdoid component. A. Im-
munohistochemistry for INI1 protein in ccRCC with rhabdoid features (10-20%), and corresponding normal kidney 
tissue from independent patients (P1 and P2), magnification 40×. Arrows indicated rhabdoid cells. B. INI1 immu-
nostaining in ccRCC and corresponding normal kidney tissue from independent patients (P3 and P4), magnification 
40×. C. Tissue microarray (TMA) from ccRCC and corresponding normal kidney sample. D. Western blot using anti-
INI1 antibody in patients samples - ccRCC and normal kidney tissue. As a loading control membrane stained with 
TCE (stain free) was used. E. qRT-PCR measurement of the SMARCB1 expression level on the same patient samples 
as in 1D. F. Western blot analysis using anti-INI1 antibody on three different human cancer cell lines serving as 
positive control. 1-MCF7, 2-MDA-MB231, 3-positive control provided by the manufacturer. G. Negative control for 
immunohistochemistry (without anti-INI1 antibody).
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formed on snap frozen ccRCC and correspond-
ing normal kidney samples. This confirmatory 
analysis showed that indeed the INI1 is less 
abundant in cancer samples when compared to 
control (Figure 1D). This observation was fully 
consistent with the results of SMARCB1 tran-
script level measurements in samples from the 
same patients as in Figure 1D using qRT-PCR 
(quantitative Real-Time PCR) method with 
SMARCB1 specific primers (Figure 1E). As a ref-
erence, primers specific to the UBI (UBIQUITIN) 
cDNA were used. The specificity of IHC was con-
firmed by both negative and positive controls 
(Figure 1F and 1G). 
Given the above observation, we decided to 
assess the extent of INI1 loss in ccRCC cancer 
cells and calculated the percentage of stained 
cells combined with the intensity of staining 
(Hscore) [25] for tumor tissue and normal kid-
ney samples. The Hscore calculation was per-
formed on 1000 of both cancer and proximal 
tube epithelial cells. This analysis showed sta-
tistically significant decrease of INI1 staining 
(p<0.0001) in ccRCC samples comparing to 
normal kidney tissue, (Figure 2A), similar 
results were obtained when only percentage of 
INI1 stained cells was counted (data not 
shown). To verify identified potential correlation 
between the reduced INI1 protein abundance 
on western blot and SMARCB1 transcription 
level (Figure 1D and 1E) in ccRCC samples we 
measured SMARCB1 (INI1) transcript level in a 
higher number of snap frozen ccRCC samples 
using qRT-PCR method with SMARCB1 specific 
primers. Statistically significant downregulation 
(p<0.05) of SMARCB1 mRNA was observed in 
cancer cells comparing to control samples 
(Figure 2B). This suggests that decrease of INI1 
protein may indeed result from reduced tran-
scription levels of SMARCB1 gene in ccRCC, 
however the mutations inactivating SMARCB1 
have not been reported for ccRCC. 
We then checked for potential correlation 
between INI1 staining and the ccRCC related 
features i.e. Fuhrman grade, tumor size, lym-
phocyte infiltration as well as other parameters 
Figure 2. Association of INI1 abundance with clincopathological component. A. Hscore of INI1 stained cells diagram 
in ccRCC samples and corresponding normal kidney tissue. B. SMARCB1 gene expression in ccRCC tumors and 
normal tissue as a control (P value <0.05). C. Hscore of INI1 stained cells in different Fuhrman grade (G1-2 and G3-
4) of ccRCC samples vs normal kidney tissue. D. Hscore of INI1 stained cells in ccRCC samples and corresponding 
control according to gender (P value <0.001 for women and P value <0.0001 for men). E. Dot and line diagram of 
INI1 stained ccRCC cells and corresponding normal kidney epithelial tube cells.
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like age, gender, etc. We observed discrete dif-
ferences in the extent of INI1 staining between 
ccRCC and corresponding control samples in 
Fuhrman grades G1-2 (p<0.0001) and G3-4 
(p<0.001) groups (data not shown), when per-
centage of staining cells was calculated, al- 
though, no differences was observed in Hscore 
between G1-2 with G3-4 (Figure 2C). Weak dif-
ferences in statistical significance were ob- 
served between males and females. In males 
the differences in INI1 staining between ccRCC 
cells and control samples were more statisti-
cally significant (p<0.0001) than in females 
group (p<0.001) (Figure 2D). The comparative 
analysis of cancer samples and corresponding 
normal kidney epithelial cells indicated decre- 
ased level of INI1 in all pairs of examined sam-
ples (Figure 2E).
Interestingly, the correlation coefficient analy-
sis showed statistically significant correlation 
between higher INI1 protein level in ccRCC cells 
and lymphocyte infiltration of the tumor, but for 
other factors like tumor size, grade, age and 
gender the INI1 level did not correlate (Table 2). 
Similarly, the multivariate analysis of all factors 
revealed statistically significant correlation 
between INI1 protein level in ccRCC and lym-
phocyte infiltration. This data strongly suggest 
the involvement of INI1 protein and most likely 
the whole SWI/SNF complex in ccRCC 
development. 
Disturbances in SMARCB1 expression contrib-
ute to poor survival 
Our study of ccRCC samples showed decrease 
of INI1 protein abundance as well as SMARCB1 
gene expression downregulation in tumor cells. 
Therefore, we decided to check if the SMARCB1 
transcript level in tumor samples correlates 
3B), however no differences were found for 
grade 2 and 4. Interestingly, most significant 
differences in survival were found for SMARCB1 
according to performance status 1 (HR=4.65 
[95% C.I 2.21-9.77], p=4.944e-05) (Figure 3C) 
but no significant associations were found for 
performance status 0, 2 and 3. Moreover, this 
study also indicated that SMARCB1 expres- 
sion level may have a predictive value only in 
male patients (HR=2.19 [95% C.I 1.18-4.05], 
p=0.0126) but not in female (Figure 3D and 
3E). This observation together with recently 
reported important role of androgen receptor in 
ccRCC development and progression [26] as 
well as direct interactions of SWI/SNF complex-
es with androgen receptor may help address 
the question why ccRCC most commonly 
affects male patients [27]. Consistently with 
the observed variabilities in the SMARCB1 
expression level, in our IHC study we also found 
distinct intensity of the INI1 staining among all 
analyzed ccRCC samples (Figure 3F) further 
confirming the importance of INI1in ccRCC.
INI1 controls genes involved in cancer progres-
sion and metastasis
Given the observation that the disturbances in 
the SMARCB1 expression contribute to poor 
survival we decided to check the extent to 
which transcriptomic alteration in ccRCC are 
caused by observed INI1 alterations. Com- 
parative analysis of ChIP seq data for INI1 
direct target genes (i.e. INI1 protein has been 
found on their loci [28]) and genes with altered 
expression in ccRCC (GEO36895) [21] resulted 
in identification of 849 common genes 
(Supplementary File 1). Among INI1 target 
genes with altered expression 478 were upreg-
ulated in ccRCC in this analysis (Figure 4A). The 
Gene Ontology analysis identified class of 
Table 2. Correlation between the INI1 staining and clinico-
pathological factors in ccRCC. The statistically significant 
value indicated by asterisk and bold (P value <0.05)
Factors r P
95% CI
Lower limit Upper limit
Lymphocyte infiltration 0.2900 0.0432* 0.009609 0.5282
Tumor size 0.04085 0.7805 -0.2431 0.3184
Fuhrman grade -0.07826 0.5930 -0.3517 0.2075
Gender 0.1004 0.4927 -0.1861 0.3711
Age -0.1825 0.2096 -0.4410 0.1041
*significant P value.
with survival rate of ccRCC pa- 
tients. Therefore we performed 
Cox proportional hazard regres-
sion on independent 177 ccRCC 
patients cohort (GSE3538) [23] 
according to performance status, 
gender, grade and stage of the dis-
ease. The statistically significant 
associations were found for SM- 
ARCB1 gene expression for exam-
ined cohort (HR=1.91 [95% C.I 
1.24-2.93], p=0.003303), (Figure 
3A) and grade 3 (HR=2.2 [95% C.I 
1.19-4.08], p=0.01245) (Figure 
INI1 in ccRCC
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Figure 3. Kaplan-Meier survival curves for ccRCC patient according to high and low SMARCB1 expression. A. Sur-
vival analysis using Cox proportional hazard model for 177 patients with diagnosed ccRCC. B. Fuhrman grade. C. 
Performance status. D and E. Gender. F. Examples of low (P7 and P8) or high (P9 and P10) intensity of IHC-staining 
for INI1 in ccRCC samples used in this study. The green and red color lines indicated patients with low and high risk. 
Numbers of patients in each group and log-rank p values, hazard ratio (HR) and confidence intervals (CI) are shown 
below the graph.
Figure 4. Set of genes misregulated in ccRCC and identified as direct INI1 target genes. A. Venn diagram of INI1 
target genes and genes upregulated in ccRCC samples. B. Selected Gene Ontology terms enriched in genes up-
regulated in ccRCC and INI1 target. C. Venn diagram of INI1 target genes and genes downregulated in ccRCC. D. 
Selected Gene Ontology terms enriched in genes downregulated in ccRCC and INI1 target. 
INI1 in ccRCC
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genes involved in various cellular processes 
including these related to cancer progression 
and metastasis formation such as: cell motility, 
blood vessels development, cell proliferation 
and programmed cell death (Figure 4B). Using 
Gene Ontology analysis we found that among 
371 genes downregulated in ccRCC and target-
ed by INI1 (Figure 4C) the following GO terms 
were enriched: cell differentiation, epithelium 
development, morphogenesis of epithelium, 
response to chemical (Figure 4D). Detailed 
analysis for genes directly targeted by INI1 with 
misregulated expression in ccRCC resulted in 
identification of genes encoding CXCL12 and 
CXCR7 proteins, which are involved in metasta-
ses formation in various cancers by CXCL12/
CXCR4/CXCR7 axis [29] (Figure 5A and 5B). 
Additionally, ccRCC is also characterized by the 
misexpression of CXCR4, however this gene 
was not found as INI1 direct target gene (Figure 
5B). The Cox proportional hazard regression 
analysis showed that the CXCL12/CXCR4/
CXCR7 axis transcript alterations correlate with 
poor prognosis (survival) for ccRCC grade 3 and 
male patients (Figure 5C-F). This indicates that 
INI1 may be directly involved in cancer progres-
sion and metastases formation. Subsequently, 
we found that overexpression of INI1 protein in 
A498 renal cancer cells (Figure 6A and 6B) 
caused downregulated expression of CXCR4 
and CXCR7 genes (Figure 6C), which provides 
evidence that INI1 loss observed in ccRCC may 
promote cancer metastases formation by direct 
regulation of CXCL12/CXCR4/CXCR7 axis in 
this type of cancer (Figure 6D). Moreover, we 
found that the overexpression of INI1 in A498 
line caused elevated expression of SMARCB1 
gene which has already been reported as the 
direct target for the INI1 protein [28]. This sug-
gests INI1-dependent regulation of SMARCB1 
gene. 
Discussion
Clear cell renal cell carcinoma is the most com-
mon renal cancer in adults. When limited to kid-
ney it can be successfully cured by surgery. 
Around 30% of patients relapse after nephrec-
tomy or has metastatic disease at the time of 
diagnosis [30] which corresponds to poor prog-
nosis. Therefore, the understanding of mecha-
nism of ccRCC development and metastases 
Figure 5. CXCL12/CXCR4/CXCR7 axis in ccRCC samples. A. CXCL12. B. CXCR4 and CXCR7 expression levels in 
ccRCC patients samples compared to normal kidney tissue. C. Survival analysis using Cox proportional hazard 
model for 177 patients with diagnosed ccRCC depending on CXCL12/CXCR4/CXCR7 genes expression. D. Fuhrman 
grade. E, F. Gender. The green and red color lines indicated patients with low and high risk, respectively. Below 
the graph are shown numbers of patients in each group and log-rank p values, hazard ratio (HR) and confidence 
intervals (CI).
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formation is very important and potentially may 
lead to development of new forms of therapy. 
The TCGA study [31] as well as some other 
reports provided evidence that the aberrations 
of the SWI/SNF chromatin remodeling complex 
(CRC) functions may play important role in 
ccRCC.
In this study we show, that INI1 - the core sub-
unit of SWI/SNF chromatin remodeling complex 
may play an important role in ccRCC develop-
ment. INI1 has been already reported as a 
tumor suppressor [32]. Mutations inactivating 
INI1 were found in various types of cancer in 
adults as well as in highly malignant pediatric 
rhabdoid tumors (MRT) [13, 14, 33-35]. In 
mouse model, the INI1 deficient xenografts 
resembles these observed in MRT, which cor-
responds with rhabdoid phenotype [36]. 
Moreover, the INI1 loss was detected in rhab-
doid tumor with minute focus of clear cell renal 
cell carcinoma in 65-year-old patient [16]. On 
the other hand, the kidney MRT in children is 
recognized as high-grade malignancy com-
posed completely of rhabdoid cells [37]. In con-
trast, another report shows that in most ccRCC 
with rhabdoid component the INI1 protein level 
was intact [17]. To clarify this contradiction we 
analyzed the INI1 protein level in three cases of 
ccRCC with rhabdoid component. All three 
cases showed strong INI1 staining and high-
grade differentiation (Fuhrman grade 4). This 
observation is in line with Kryvenko statement 
that rhabdoid component of ccRCC is probably 
not a distinct type of cancer but rather dedif-
ferentiated form of high-grade ccRCC, not relat-
ed to pediatric rhabdoid tumors [24]. This con-
clusion is further supported by the study of 
Figure 6. INI1 influences CXCL12/CXCR4/CXCR7 chemokine axis. A. INI1-FLAG overexpression in A498 cells, which 
correspond with ccRCC grade 2. As a loading control membrane stained with TCE (stain free) was used. B. Western 
blot with anti-INI1 antibody demonstrating increase of INI1 abundance in A498 cell line overexpressing INI1 pro-
tein. As a loading control membrane stained with TCE (stain free) was used. C. qRT-PCR analysis for CXCR4, CXCR7 
and SMARCB1 (endogenous transcript) genes expression in A498 cell lines overexpressing INI1 protein. D. Model 
describing self-regulation of the SMARCB1 gene by INI1 protein and the interdependence of INI1, AR pathway and 
CXCL12/CXCR4/CXCR7 axis. 
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Agaimy and colleagues, who analyzed 32 cases 
of undifferentiated and rhabdoid RCC and 
found that 4 were INI1 negative, 10 showed 
reduced INI1 and 18 exhibited intact INI1 pro-
tein level [17]. 
Interestingly, in contrast to the rhabdoid com-
ponent of ccRCC, statistically significant down-
regulation of INI1 protein in conventional ccRCC 
cells was found in our study. Moreover, we 
found the decrease of INI1 protein level in all 
ccRCC cases included in this study. We also 
checked the relationships between INI1 protein 
and mRNA in some of ccRCC cases and found 
that the decrease of protein level correlated 
with significantly lower SMARCB1 transcript 
level in ccRCC cancer cells when compared to 
normal kidney tube epithelial cells. The 
decrease of INI1 protein level was independent 
of Fuhrman grade, but discrete differences in 
statistical significance were found between 
grade 1-2 and 3-4 and gender. Using Cox pro-
portional hazard model analysis we found that 
the higher expression level of SMARCB1 in the 
tumor correlates with poor prognosis in the 
male group, however there was no correlation 
in female patients. This analysis also showed 
correlation with poor prognosis for patients 
with Fuhrman grade 3 interestingly the stron-
gest correlation was found for patients in rela-
tive good condition. 
Correlation between higher expression of 
SMARCB1 gene in some ccRCC tumor samples 
(however still decreased when compared to the 
control tissue) and poor prognosis for male 
patients may be likely explained by the involve-
ment of SWI/SNF CRC in androgen biosynthe-
sis pathway according to ENCODE database 
[38, 39] and regulation of androgen dependent 
genes by direct interacting with androgen 
receptor (AR) [40], and AR association with 
higher tumor stage and promotion of ccRCC 
migration and invasion [26]. However further 
confirmatory study is required. 
Our comparative analysis of INI1 target genes 
and genes misregulated in ccRCC samples fol-
lowed by the Gene Ontology classification 
resulted in identification of GO terms statisti-
cally enriched for INI1-target genes upregulated 
in ccRCC, related to cancer progression and 
metastasis formation. They were: programmed 
cell death e.g. PDK1 (3-phosphoinositide-
dependent protein kinase-1) which suppresses 
apoptosis when overactive [41]; cell prolifera-
tion, blood vessels development, leukocyte 
activation and cell motility. GO terms statisti-
cally enriched for INI1-target genes downregu-
lated in ccRCC were related to cell differentia-
tion, epithelium development and morpho- 
genesis, and response to chemicals. Close 
inspection of the INI1-target genes misregulat-
ed in ccRCC resulted in identification of CXCR7 
(upregulated) and CXCL12 (downregulated) 
both belonging to the CXCR4/CXCR7/CXCL12 
chemokine axis, well known regulators of tumor 
growth and metastasis formation in many types 
of cancer [29]. The Cox analysis showed that 
affected expression of these genes correlates 
with poor prognosis for ccRCC patients. 
Noteworthy, this correlation was significant for 
ccRCC Fuhrman grade 3 and male group only, 
analogous to what was observed for SMARCB1 
expression. It has already been reported that 
CXCR4/CXCR7/CXCL12 axis and AR interplay to 
promote cancer progression and metastasis 
formation, as CXCL12/CXCR4 promote ligand 
independent activation of androgen receptor 
[42]. AR together with CXCR4 and CXCR7 regu-
late the CXCL12 dependent cell motility in pros-
tate cancer [43]. Consistently, the overexpres-
sion of INI1 in A498 cancer cells which 
corresponds to clear cell renal cell carcinoma 
grade 2, caused downregulated expression of 
CXCR4 and CXCR7 genes. Our observation 
regarding the INI1-dependent CXCR4 and 
CXCR7 regulation is in line with the recently 
reported strong effect of INI1 reexpression in 
MRT cell lines, where the restored expression 
of INI1 protein induced G1 cell cycle arrest and 
lead to the modification of p21 or p16 loci 
expression [44]. In summary, our data strongly 
suggest close relation of INI1 and ccRCC devel-
opment, tumor progression and metastases 
formation. So far the knowledge about tran-
scriptional control of SMARCB1 gene expres-
sion is strongly limited, however there are some 
evidences indicating that among other mecha-
nisms the SWI/SNF complex may be directly 
involved in this process [28, 45]. In fact, during 
our study we found that the INI1 overexpres-
sion in A498 cell line indeed caused elevated 
expression of the SMARCB1 gene. This finding 
clearly indicated that the alterations of self-
control of SMARCB1 expression by the INI1 
(and likely INI1-containing SWI/SNF complex) 
may be one of the possible explanations of 
observed INI1 loss in ccRCC. On the other hand, 
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we can’t exclude the existence of other mecha-
nisms controlling SMARCB1 expression level 
like i.e. the SWI/SNF and Polycomb (PcG, 
Polycomb Repressive Group) antagonism (SWI/
SNF complex has been reported as the impor-
tant factor in the eviction of Polycomb proteins 
[46]) which may result in altered DNA or histone 
methylation on SMARCB1 promoter or the exis-
tence of a long non-coding RNA which may 
interfere with SMARCB1 transcript, or other 
unrecognized yet mechanisms. However, the 
complete elucidation of the mechanism under-
lying decreased expression of SMARCB1 gene 
in ccRCC requires further examination.
Proper SWI/SNF complex function usually 
requires INI1 protein [10, 47, 48, 49]. However 
there is emerging evidence that in some tumors 
the SWI/SNF complex activity may act indepen-
dently of INI1 [50] and INI1 protein deficiency in 
cancer cells redefines the SWI/SNF subunits 
composition [51].
Alteration in stoichiometry of complex composi-
tion is likely to lead to loss of proper SWI/SNF 
function or gaining of a novel, cancer related 
function, which may cause dramatic conse-
quences in global gene expression by transcrip-
tional regulation, epigenetic and higher order 
chromatin structure disturbances. It has been 
already shown, that during pancreatic cancer 
development the BRG1 ATPase (another core 
subunit of SWI/SNF CRC) acts as either tumor 
suppressor or oncogene depending on stage of 
the disease [52]. This may explain the correla-
tion between higher (although decreased when 
compared to control kidney tissue) SMARCB1 
gene expression and poor prognosis observed 
in our study. Additionally, the identified correla-
tion of stronger INI1 staining in ccRCC cells with 
lymphocyte infiltration supports this hypothesis 
as consistently immune infiltration in ccRCC 
associates with poor prognosis in male 
patients, higher tumor grade and stage [53]. 
Taken together our findings support the hypoth-
esis that downregulation of INI1, the core sub-
unit of SWI/SNF CRC may occur on a very early 
stage of carcinogenesis, and can promote 
ccRCC development and poor prognosis. On 
the other hand, as the ccRCC with rhabdoid 
component shows higher aggressiveness, poor 
prognosis and usually intact INI1 protein level, 
the involvement of INI1 in cancer progression 
and metastases still requires further careful 
investigation.
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